$INDV News

Indivior Pharmaceuticals (NASDAQ:INDV) Passes Minervini Trend Template and High Growth Momentum Screen

Indivior Pharma Announces Findings From Two New Real-World Evidence Studies Show Adherence To Extended-Release Buprenorphine Is Associated With Lower Relapse Risk And Reduced Healthcare Utilization

Indivior Pharmaceuticals Enters Into $175M Accelerated Share Repurchase Agreement With Barclays Bank, Executed Under Indivior's Existing $400M Share Repurchase Program

Indivior Pharmaceuticals, Inc. 2026 Q1 - Results - Earnings Call Presentation

Indivior Pharmaceuticals, Inc. (INDV) Q1 2026 Earnings Call Transcript

Indivior Pharmaceuticals Inc (NASDAQ:INDV) Smashes Q1 Estimates and Lifts Full-Year Outlook as SUBLOCADE Sales Surge

Indivior Pharmaceuticals Raises FY2026 Sales Guidance from $1.125B-$1.195B to $1.215B-$1.285B vs $1.156B Est

Indivior Q1 Adj. EPS $0.96 Beats $0.66 Estimate, Sales $317.000M Beat $272.840M Estimate

Indivior Pharmaceuticals Awarded ~$748.9M U.S. Department Of Veterans Affairs Drug Supply Contract, Pharmaceutical Preparation Manufacturing

Indivior Pharmaceuticals Inc (NASDAQ:INDV) Shows High Growth Momentum and Technical Breakout Potential

Indivior: Still Attractive After FY25 Earnings Beat

Reported Earlier, Indivior Prices Upsized $450M Convertible Senior Notes Offering At 0.625% Due 2031

Indivior Pharmaceuticals shares are trading lower after the company announced its intention to commence a $400 million senior notes offering.

Indivior Pharmaceuticals Intends To Commence $400M Senior Notes Offering

Indivior Announces Findings From Retrospective Observational Study Showing Adherence To SUBLOCADE Monthly Injectable Buprenorphine Linked To Lower Healthcare Utilization And Costs In Opioid Use Disorder

Indivior Pharmaceuticals, Inc. 2025 Q4 - Results - Earnings Call Presentation

Indivior Pharmaceuticals, Inc. (INDV) Q4 2025 Earnings Call Transcript

Indivior Pharmaceuticals Inc (NASDAQ:INDV) Surpasses Q4 2025 Estimates and Provides Strong 2026 Outlook

Insights into Indivior Pharmaceuticals Q4 Earnings

Indivior Pharmaceuticals Affirms FY2026 Sales Guidance of $1.125B-$1.195B